

IN THE UNITED STATES PATENT OFFICE

#6
6/28/98
Decap

In re Application of: Klimko et al.


Serial Number: 08/917,795

Filed: August 21, 1997

For: USE OF CLOPROSTENOL AND FLUPROSTENOL ANALOGUES TO
TREAT GLAUCOMA AND OCULAR HYPERTENSION

REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents
Application Processing Division
Customer Correction Branch
Washington, D.C. 20231



Sir:

Applicants respectfully request that the official filing receipt issued for the above-referenced case be corrected. A copy of the filing receipt as originally issued is attached, with the correction typed and highlighted in yellow.

As reflected on the attached receipt the information identified in the "continuing data" section is incomplete. This information was correctly stated in the Preliminary Amendment to this continuation application dated August 21, 1997.

In order to avoid future confusion, applicants respectfully request that a corrected filing receipt be issued to reflect the correct information.

Respectfully submitted,
ALCON LABORATORIES, INC.

Date: 5-28-98

By: 
Barry L. Copeland
Registration No. 34,801

Address for Correspondence:

Barry L. Copeland
Intellectual Property Law and R&D Counsel (Q-148)
Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, Texas 76134
(817) 551-4322
Attorney Docket No. 1407B

FILIN


T



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/917,795	08/21/97	1611	\$814.00	1407B	0	22	2

BARRY L COPELAND
PATENT DEPT Q 148
ALCON LABORATORIES INC
6201 SOUTH FREEWAY
FORT WORTH TX 76134



Receipt is acknowledged of this patent application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

PETER G. KLIMKO, FORT WORTH, TX; JOHN E. BISHOP, GROTON, MA; VERNEY L. SALLEE, BURLESON, TX; PAUL W. ZINKE, FORT WORTH, TX.

CONTINUING DATA AS CLAIMED BY APPLICANT-

~~THIS APPLN IS A CIP OF 08/101,598 08/03/93 PAT 5,510,383 C~~

FOREIGN FILING LICENSE GRANTED 01/14/98

TITLE

USE OF CLOPROSTENOL AND FLUPROSTENOL ANALOGUES TO TREAT GLAUCOMA AND OCULAR HYPERTENSION

PRELIMINARY CLASS: 514

This application is a continuation of U.S. Patent Application Serial No. 08/769,293 filed December 18, 1996, now U.S. Patent No. 5,665,773, which is a continuation of U.S. Patent Application Serial No. 08/280,681 filed July 26, 1994, now abandoned, which is a continuation-in-part of U.S. Patent Application Serial No. 08/101,598 filed August 3, 1993, now U.S. Patent No. 5,510,383.

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). This license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license has been granted under 37 CFR 5.13.

This license is to be retained by the licensee and may be used at anytime on or after the effective date thereof unless it is revoked. This license is transferrable to any related application(s) filed under 37 CFR 1.62 which meet the provisions of 37 CFR 5.15(a)(4). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR, Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12 (b), if a license is desired.